靶向HPV的siRNAs技术治疗宫颈癌研究的现状与挑战

The present advances and challenges of siRNAs targeted to HPV in cervical carcinoma therapy

小干扰RNA(small interfering RNAs,siRNAs)是近年来靶向治疗人类乳头瘤病毒(human papillomavirus,HPV)的分子生物学研究热点。该技术在抗HPV的靶向性研究中具有高特异性、放大效应、作用稳定、并可遗传等特征,为宫颈癌防治中抗HPV基因治疗提供了新途径。但siRNAs技术研发的核酸药物应用于临床仍面临者许多挑战和尚未解决的问题。今后抗HPV治疗的发展方向和研究重点仍将是采用siRNA技术在HPV相应位点阻断病毒复制,联合抗病毒的全身免疫调节的综合治疗以提高疗效。

Small interfering RNAs（siRNAs） technique is the hot topic of the molecular biology research on the target therapy of human papillomavirus（HPV）.This technique has the characteristics of high specificity,high efficiency,high stability,and being hereditable,which provides a new strategy for the anti-HPV gene in cervical carcinoma therapy.However,there are still many challenges and problems in the use of the medicine from this technology to the clinic.The developmental direction and key point on the treatment of HPV are to inhibit the replication of the virus at the corresponding site by siRNA,combined with systemic anti-virus immunology regulation to improve the therapeutic effect.